Atria Wealth Solutions’s Teva Pharmaceuticals TEVA Stock Holding History

Atria Wealth Solutions’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,796	Closed	-$273K	–	2046
2024 Q2	$273K	Hold	16,796	–	–	﹤0.01%	1566
2024 Q1	$237K	Buy	16,796 +13	+0.1%	+$164	﹤0.01%	1715
2023 Q4	$175K	Sell	16,783 -1,000	-6%	-$9.34K	﹤0.01%	1801
2023 Q3	$181K	Hold	17,783	–	–	﹤0.01%	1723
2023 Q2	$134K	Sell	17,783 -96	-0.5%	-$778	﹤0.01%	1754
2023 Q1	$158K	Sell	17,879 -26	-0.1%	-$257	﹤0.01%	1711
2022 Q4	$163K	Sell	17,905 -10,854	-38%	-$94.7K	﹤0.01%	1646
2022 Q3	$232K	Buy	+28,759	New	+$254K	﹤0.01%	1471
2022 Q2	–	Sell	-30,379	Closed	-$265K	–	1884
2022 Q1	$285K	Buy	+30,379	New	+$254K	﹤0.01%	1348

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Atria Wealth Solutions's TEVA Position: Q3 2024 in Review

Atria Wealth Solutions sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 16,796 shares — an estimated $273K sold.

Atria Wealth Solutions first reported a position in TEVA in Q1 2022 and held it in 9 quarters. The position peaked at $285K in Q1 2022. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

Atria Wealth Solutions reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Atria Wealth Solutions sold 16,796 Teva Pharmaceuticals shares in Q3 2024, an estimated $273K.
Atria Wealth Solutions first reported a position in Teva Pharmaceuticals in Q1 2022 and held it in 9 quarters.
Atria Wealth Solutions's Teva Pharmaceuticals position peaked at $285K in Q1 2022.
542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Atria Wealth Solutions's 13F filing for Q3 2024, filed 8 Nov 2024.